Journal
CURRENT OPINION IN UROLOGY
Volume 18, Issue 5, Pages 533-539Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOU.0b013e32830b8910
Keywords
bladder cancer; clinical guidelines; cost-effectiveness; evidence-based medicine; health economics
Categories
Funding
- NCRR NIH HHS [1 UL1 RR024160-01, UL1 RR024160] Funding Source: Medline
Ask authors/readers for more resources
Purpose of review The diagnosis and treatment of bladder cancer represents a significant financial burden to the population in the United States. Therapeutic advances in bladder cancer care have come at a high cost to payers, providers, and patients. This study describes the principals of cost-effectiveness evaluation in healthcare and provides recommendations for a more economical use of resources in bladder cancer care. Recent findings Although several studies have demonstrated that bladder cancer is a common disease associated with substantial economic burden for patients and society, the evidence supporting the cost-effectiveness of many interventions in bladder cancer care is limited and of insufficient quality. In addition, very little is known about quality of life, the preferred outcome measure for economic evaluations, associated with bladder cancer states and treatments. Moreover, current clinical guidelines for bladder cancer care do not incorporate economic factors when evaluating clinical pathways. Summary Although cost-effectiveness studies in bladder cancer could allow us to know how healthcare dollars are being spent and assist in determining more effective ways to allocate resources, most of the currently used interventions have not undergone economic assessment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available